A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-05-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: heartcardiacmsbaselinecarcinoma
  Phrases that lowered it: participantparticipantsdayindexsafety
• Drug's FAERS reports marked serious: 47.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 19 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 7.4% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 100 (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Maximum age: 80 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Lemborexant in Chinese Participants With Insomnia Disorder NCT04549168 · started 2020 · scored riskier than 18% of active trials completed
• Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) NCT02783729 · started 2016 · scored riskier than 68% of active trials completed
• Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder NCT02350309 · started 2014 · scored riskier than 19% of active trials completed
• Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2) NCT02952820 · started 2016 · scored riskier than 58% of active trials completed
• A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia NCT04009577 · started 2019 · scored riskier than 36% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.